Latest Breaking News On - Jonathanb zung - Page 1 : comparemela.com

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

Jonathanb zungCompany fourthRoche groupDrug administrationCuris incPrnewswire curis incChief development officerInducement grantFourth amendedIncentive planAim lymphomaAim leukemiaOrphan drug designationTakeaim leukemiaHealth care amp hospitalsMedical pharmaceuticals